The Department of Pediatrics, West China Second University Hospital of Sichuan University, No 20 Third Section, Renmin Nan Road, Chengdu, Sichuan, 610041, China.
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, Sichuan, 610041, China.
BMC Urol. 2024 Apr 25;24(1):97. doi: 10.1186/s12894-024-01486-9.
Overactive bladder is a common chronic urological disorder in children, liable to impact normal social activities, disrupt sleep and even impair self-esteem. We aimed to evaluate the efficacy and safety of solifenacin combined with biofeedback for paediatric overactive bladder.
Forty-five children with overactive bladder were enrolled and divided into three groups: 15 patients in Group A were treated with solifenacin, 15 cases in Group B with biofeedback, and the other 15 patients in Group C with the combination of solifenacin plus biofeedback. Each group was subdivided into the non-urge incontinence (non-UI) and urge incontinence (UI) groups. The remission rates were compared among the three groups at 2, 4, 8 and 12 weeks from the beginning of treatment. The side effects of solifenacin were recorded and followed up.
After 2 weeks since initial treatment, the complete response rates were 33.3% (5/15), 20.0% (3/15), and 53.3% (8/15) in the three groups. At 4 weeks, the complete remission rates were 46.7% (7/15), 33.3% (5/15), and 60.0% (9/15) respectively. Moreover, the complete remission rates of the UI groups were higher than the non-UI groups (p < 0.05). At 8 weeks, the complete response rates were 53.3% (8/15), 40.0% (6/15), and 67.7% (10/15). At 12 weeks, the complete response rates were 67.8% (10/15), 60.0% (9/15), and 86.7% (13/15). The complete response rates were higher and urodynamic parameters were improved obviously in group C than the other two groups (p < 0.05) during the follow-ups. The median voiding frequency decreased and median functional bladder capacity increased obviously in Group C after 4 weeks (p < 0.05). Dry mouth was observed in 2 patients (4.4%). 2 patients experienced constipation (4.4%), and neither case was severe. The symptoms of these four patients had relieved by reducing the dose of solifenacin.
Solifenacin combined with biofeedback had good efficacy and compliance for children experiencing overactive bladder. It took only 2 weeks to achieve the complete response rate over 50%, especially for the improvement of UI symptoms.
膀胱过度活动症是儿童常见的慢性泌尿系统疾病，容易影响正常的社会活动、破坏睡眠甚至损害自尊心。我们旨在评估索利那新联合生物反馈治疗儿童膀胱过度活动症的疗效和安全性。
共纳入 45 例膀胱过度活动症患儿，分为三组：A 组 15 例采用索利那新治疗，B 组 15 例采用生物反馈治疗，C 组 15 例采用索利那新联合生物反馈治疗。每组均分为非急迫性尿失禁（非 UI）和急迫性尿失禁（UI）亚组。治疗开始后 2、4、8 和 12 周比较三组的缓解率。记录索利那新的不良反应并进行随访。
治疗开始后 2 周，三组完全缓解率分别为 33.3%（5/15）、20.0%（3/15）和 53.3%（8/15）。治疗 4 周后，三组完全缓解率分别为 46.7%（7/15）、33.3%（5/15）和 60.0%（9/15），UI 组的完全缓解率均高于非 UI 组（p<0.05）。治疗 8 周后，三组完全缓解率分别为 53.3%（8/15）、40.0%（6/15）和 67.7%（10/15）。治疗 12 周后，三组完全缓解率分别为 67.8%（10/15）、60.0%（9/15）和 86.7%（13/15）。随访期间，C 组的完全缓解率更高，尿动力学参数改善更明显（p<0.05）。C 组治疗 4 周后排尿频率中位数降低，功能性膀胱容量中位数增加明显（p<0.05）。有 2 例（4.4%）患者出现口干，2 例（4.4%）患者出现便秘，但均不严重。减少索利那新剂量后，这 4 例患者的症状均缓解。
索利那新联合生物反馈治疗儿童膀胱过度活动症疗效好、依从性高，完全缓解率超过 50%仅需 2 周，尤其对改善 UI 症状效果显著。
